Immunisation – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:02 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Immunisation – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Immune Response of the 20-Valent Pneumococcal Vaccine in Adults with Fever and High Risk for Pneumococcal Infection https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-the-20-valent-pneumococcal-vaccine-in-adults-with-fever-and-high-risk-for-pneumococcal-infection/ Wed, 29 Apr 2026 15:03:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-immune-response-of-the-20-valent-pneumococcal-vaccine-in-adults-with-fever-and-high-risk-for-pneumococcal-infection/ This clinical trial is focused on studying the effects of the 20-Valent pneumococcal conjugate vaccine (PCV-20) in adults who are at medium or high risk for pneumococcal infections. Pneumococcal infections are caused by bacteria that can lead to serious illnesses like pneumonia, meningitis, and bloodstream infections. The vaccine being tested, known as Prevenar 20, is designed to protect against 20 different types of these bacteria. The study aims to compare the immune response of patients who receive the vaccine during an acute febrile illness, which is a sudden fever, to those who receive it after their fever has resolved.

Participants in the study will be randomly assigned to one of two groups. One group will receive the vaccine while they are experiencing a fever, and the other group will receive it 15 to 58 days after their fever has subsided. The study will monitor the immune response of participants one month after vaccination to determine if the timing of the vaccine affects its effectiveness. The study will also track the safety of the vaccine by recording any side effects or reactions that occur within a month after vaccination.

In addition to the primary focus on immune response and safety, the study will also look at other factors over a year, such as the number of respiratory infections and confirmed Streptococcus pneumoniae infections in participants. The study will explore the diversity of gut bacteria and the presence of specific immune cells and antibodies related to the vaccine. This research will help determine the best timing for administering the PCV-20 vaccine to adults at risk for pneumococcal infections.

]]> Study on the Effectiveness of Pneumococcal Vaccines PCV13 and PPV23 in Adults with Acute Leukemia or Lymphoma Undergoing Chemotherapy https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-pneumococcal-vaccines-pcv13-and-ppv23-in-adults-with-acute-leukemia-or-lymphoma-undergoing-chemotherapy/ Wed, 29 Apr 2026 14:22:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-pneumococcal-vaccines-pcv13-and-ppv23-in-adults-with-acute-leukemia-or-lymphoma-undergoing-chemotherapy/ This clinical trial is focused on studying the effectiveness of a combined vaccination strategy against *pneumococcal infections* in adults who have been treated for *acute myeloblastic leukemia* or *lymphoma*. The study involves two vaccines: *Prevenar 13*, which is a pneumococcal polysaccharide conjugate vaccine, and *Pneumovax*, a pneumococcal polysaccharide vaccine. The purpose of the study is to evaluate how well the immune system responds to this vaccination strategy.

Participants in the study will receive an injection of *Prevenar 13*, followed by an injection of *Pneumovax* two months later. The study will monitor the immune response one month after the complete vaccination regimen. The goal is to determine if the combined vaccination strategy effectively boosts the immune system’s ability to fight pneumococcal infections, which are caused by bacteria that can lead to serious illnesses like pneumonia.

The study will track the participants’ immune responses over time, checking for specific markers in the blood that indicate a strong defense against pneumococcal bacteria. This includes measuring levels of antibodies, which are proteins the body makes to fight infections. The study will also look at any side effects from the vaccines and assess how well the vaccines work in preventing infections. The results will help understand the best way to protect patients with *acute myeloblastic leukemia* or *lymphoma* from pneumococcal infections.

]]>